Page 4 - Nasdaq Ormp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Wall Street brokerages expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) to report sales of $700,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings. Oramed Pharmaceuticals posted sales of $680,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of […]

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Thursday. A number of other research firms have also recently commented on ORMP. Cantor Fitzgerald initiated coverage on Oramed Pharmaceuticals in a research report on Friday, February 18th. They set an “overweight” […]

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) has earned an average rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price target among […]

Equities analysts expect that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) will report earnings per share of ($0.19) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.15). Oramed Pharmaceuticals posted earnings […]

Brokerages expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) to announce sales of $700,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings. Oramed Pharmaceuticals posted sales of $670,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of […]